Tazobactam (CL-298741)
(Synonyms: 他唑巴坦; 三唑巴坦; 他唑巴坦酸; CL-298741; YTR-830H) 目录号 : GC33927A β-lactamase inhibitor
Cas No.:89786-04-9
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Tazobactam is a β-lactamase inhibitor with greater activity against Ambler class A serine penicillinases and class C cephalosporinases, including TEM-1, SHV-1, and P99 (IC50s = 97, 150, and 8.5 nM, respectively) than class B metallo-β-lactamases and the class D oxacillinase OXA-1 (IC50s = 400,000 and 1,400 nM, respectively).1 However, it also inhibits the class D oxacillinase OXA-2 (IC50 = 10 nM). Tazobactam, in combination with piperacillin, is active against Gram-positive (MIC90s = 2-128 ?g/ml) and Gram-negative bacteria (MIC90s = 4-128 ?g/ml).2 In a neutropenic mouse model of thigh infection, tazobactam potentiates the activity of ceftolozane against Enterobacteriaceae.3 Formulations containing tazobactam, alone and in combination with piperacillin, have been used in the treatment of β-lacatamase-producing bacteria.
1.Drawz, S.M., and Bonomo, R.A.Three decades of β-lactamase inhibitorsClin. Microbiol. Rev.23(1)160-201(2010) 2.Jones, R.N., Pfaller, M.A., Fuchs, P.C., et al.Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strainsDiagn. Microbiol. Infect. Dis.12(6)489-494(1989) 3.Craig, W.A., and Andes, D.R.In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic miceAntimicrob. Agents Chemother.57(4)1577-1582(2013)
Cas No. | 89786-04-9 | SDF | |
别名 | 他唑巴坦; 三唑巴坦; 他唑巴坦酸; CL-298741; YTR-830H | ||
Canonical SMILES | O=C([C@@H]([C@@](CN1N=NC=C1)(C)S([C@]2([H])C3)(=O)=O)N2C3=O)O | ||
分子式 | C10H12N4O5S | 分子量 | 300.29 |
溶解度 | DMSO : ≥ 35 mg/mL (116.55 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.3301 mL | 16.6506 mL | 33.3011 mL |
5 mM | 0.666 mL | 3.3301 mL | 6.6602 mL |
10 mM | 0.333 mL | 1.6651 mL | 3.3301 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。